Impact of COVID-19 on the time to counseling and treatment of prostate cancer
Standard
Impact of COVID-19 on the time to counseling and treatment of prostate cancer. / Filipas, Dejan K; Pose, Randi M; Marks, Phillip; Tennstedt, Pierre; Beyer, Burkhard; Tilki, Derya; Isbarn, Hendrik; Maurer, Tobias; Ludwig, Tim A; Heinzer, Hans; Steuber, Thomas.
in: AGING MALE, Jahrgang 27, Nr. 1, 2347465, 05.2024.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of COVID-19 on the time to counseling and treatment of prostate cancer
AU - Filipas, Dejan K
AU - Pose, Randi M
AU - Marks, Phillip
AU - Tennstedt, Pierre
AU - Beyer, Burkhard
AU - Tilki, Derya
AU - Isbarn, Hendrik
AU - Maurer, Tobias
AU - Ludwig, Tim A
AU - Heinzer, Hans
AU - Steuber, Thomas
PY - 2024/5
Y1 - 2024/5
N2 - PURPOSE: This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a "minimal contact concept," which postponed clinical examinations until the day of admission.METHODS: We analyzed patient data from a tertiary care center from 2018 to September 2021. The focus was on comparing the time intervals from ID to TC and from ID to RP before and during the CP.RESULTS: Of 12,255 patients, 6,073 (61.6%) were treated before and 3,791 (38.4%) during the CP. The median time from ID to TC reduced from 37 days (IQR: 21 - 58d) pre-CP to 32 days (IQR: 20 - 50d) during CP (p < 0.001). Similarly, the time from ID to RP decreased from 98 days (IQR: 70 - 141d) to 75 days (IQR: 55 - 108d; p < 0.001) during the CP. There was a significant decrease in low-risk tumor cases at ID (18.9% vs. 21.4%; p = 0.003) and post-RP (4% vs. 6.7%; p < 0.001) during the CP.CONCLUSION: Our findings suggest that the COVID-19 pandemic facilitated more timely treatment of prostate cancer, suggesting potential benefits for both low-risk and aggressive tumor management through expedited clinical procedures.
AB - PURPOSE: This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a "minimal contact concept," which postponed clinical examinations until the day of admission.METHODS: We analyzed patient data from a tertiary care center from 2018 to September 2021. The focus was on comparing the time intervals from ID to TC and from ID to RP before and during the CP.RESULTS: Of 12,255 patients, 6,073 (61.6%) were treated before and 3,791 (38.4%) during the CP. The median time from ID to TC reduced from 37 days (IQR: 21 - 58d) pre-CP to 32 days (IQR: 20 - 50d) during CP (p < 0.001). Similarly, the time from ID to RP decreased from 98 days (IQR: 70 - 141d) to 75 days (IQR: 55 - 108d; p < 0.001) during the CP. There was a significant decrease in low-risk tumor cases at ID (18.9% vs. 21.4%; p = 0.003) and post-RP (4% vs. 6.7%; p < 0.001) during the CP.CONCLUSION: Our findings suggest that the COVID-19 pandemic facilitated more timely treatment of prostate cancer, suggesting potential benefits for both low-risk and aggressive tumor management through expedited clinical procedures.
KW - Humans
KW - Male
KW - Prostatic Neoplasms/therapy
KW - COVID-19/epidemiology
KW - Aged
KW - Prostatectomy/methods
KW - Time-to-Treatment/statistics & numerical data
KW - Middle Aged
KW - SARS-CoV-2
KW - Counseling
KW - Retrospective Studies
KW - Time Factors
U2 - 10.1080/13685538.2024.2347465
DO - 10.1080/13685538.2024.2347465
M3 - SCORING: Journal article
C2 - 38712892
VL - 27
JO - AGING MALE
JF - AGING MALE
SN - 1368-5538
IS - 1
M1 - 2347465
ER -
